Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :


By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :


Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Zelda Therapeutics Ltd ZLDAF

Zelda Therapeutics Ltd is an Australia-based biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in a breast, brain, and pancreatic cancer.

View modes: 


PERTH, AUSTRALIA Thursday 6th December 2018: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery (“SUDA”), today announces that it has entered into a fully funded more


see some news here:  rate and reply

C.BOSS Appoints Head of Sales w/ Expertise in Edible Mushroom Wellness Products

The global edible mushrooms market is expected to grow at a CAGR of 7.95% to grow to US$62 billion by 2023, increasing from US$42 billion in 2018, according to a report by Research and Markets. Grand View Research reports that the global healthy snacks market size is expected to reach US$32 billion by 2025. more


Anybody following this?   rate and reply

Short interest decreased by 74.6%

ZELDA THERAPEUTICS LTD ORD AUSTR (OTCMKTS:ZLDAF) Just Reported Decreased Shorts January 10, 2018 - By Richard Conner   The stock of ZELDA THERAPEUTICS LTD ORD AUSTR ( more


Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.